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REPLY
My fellow authors and I appreciate the comments expressed in
Dr. Horvath’s letter, which largely claim that the sole reason for the
negative results demonstrated in our study (1) relates to procedural
differences between surgical versus percutaneous transmyocardial
laser revascularization (TMR). Although we acknowledged in our
study that full-thickness transmyocardial laser channels at surgery
are indeed different from smaller non–full-thickness catheter-
based transendocardial channels (1), we believe strongly that our
blinded study accurately highlights the potent placebo effects in
this patient population. As such, this causes us to doubt the clinical
benefits referenced in the surgical TMR literature. Our reasons are
as follows: 1) of the 17 surgical TMR studies cited in our study (11
observational studies and 6 randomized trials vs. “best” medical
therapy), the main benefit is subjective improvement in angina
class, and in most studies performing quantitative ischemia assess-
ments (such as nuclear perfusion imaging) there were no improve-
ments after surgical TMR. 2) Without controlling for the placebo
effects, the nonblinded percutaneous TMR literature also showed
the same magnitude of subjective angina improvement as seen with
surgical TMR, which in our study was neutralized in the presence
of a sham control group. 3) There is no plausible and scientifically
creditable explanation for the anti-ischemic actions of percutane-
ous or surgical TMR, as the prevailing theories of patent channels,
epicardial denervation, and local angiogenesis have not been
validated in experimental models or in patients.
To compound matters, in a retrospective analysis from the
Society of Thoracic Surgeons (STS), the National Cardiac Data-
base identified 3,717 patients at 173 U.S. hospitals who had
received surgical TMR procedures over a 4-year period, and of
these procedures, only 17% were TMR alone, whereas 67% were
TMR  coronary artery bypass surgery (CABG), which is an
unapproved indication (2). Thus far, there has been a single blinded,
randomized trial comparing TMR  CABG versus CABG alone
in 263 patients, and the clinical outcomes indicated no improve-
ment in angina and exercise treadmill results with the combined
procedure (3).
Finally, based on our disquieting experiences with percutaneous
TMR in our study, we would strongly urge additional validating,
blinded, randomized clinical trials to examine the safety and
efficacy of combined TMR  CABG before widespread clinical
use is advocated in the “real world.”
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How Does Caffeine
Increase Exercise Capacity But
Decrease Myocardial Flow Reserve?
I read with interest a recent report by Namdar et al. (1) entitled,
“Caffeine Decreases Exercise-Induced Myocardial Flow Reserve.”
The investigators highlighted some study limitations but failed to
mention the potential order effect with the dosing of caffeine. All
subjects in both groups completed the exercise testing without
caffeine ingestion first and then repeated the testing 1 h later
following a 200-mg dose of caffeine. Previous research by our
group has shown that prior exercise alters the sensitivity of users of
caffeine and makes them respond like caffeine-naive subjects
during subsequent exercise tests (2). This effect of previous exercise
was evident 5 h following the earlier exercise challenge, as we had
also previously demonstrated that the ergogenic effect of a 5-mg/kg
dose of caffeine lasted for 6 h for caffeine-naive subjects in contrast
to the shorter 3-h benefit noted for caffeine users (3). The
adenosine receptor sensitivity, therefore, may have been altered
before the caffeine exercise test. A better design perhaps would
have been to increase subject numbers and assign subjects to a
placebo or caffeine group where subjects were matched according
to fitness and caffeine habituation.
Namdar et al. (1) also make no reference to the exercise science
literature that has reported a fairly consistent ergogenic effect of
caffeine on exercise performance with no evidence of altered
oxygen consumption or cardiac output (4), and that caffeine has
been shown to demonstrate its ergogenic effect even more so
during acute hypobaric exposure (5,6). Exactly how the findings
from this current study can be viewed in terms of this other
literature is puzzling.
Finally, care must also be taken in the generalization of findings
with the ingestion of caffeine to the consumption of coffee. We
know that other ingredients in coffee may interfere with the
ergogenic effect of caffeine (7) and these other ingredients can also
counter the negative effects of caffeine on glucose tolerance (8–10).
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REPLY
Dr. McLellan points out that exercise has been shown to make
subjects respond to subsequent exercise like caffeine-naïve subjects.
We welcome this information, which seems to further strengthen
our results (1), as it confirms that the sensitivity to caffeine is more
pronounced during exercise.
However, based on our power calculation we cannot support the
statement that increasing the study population and splitting it up
into placebo and caffeine groups would have improved the quality
of the study; as with the crossover design, each subject served as its
own control, an advantage that would have been lost following the
advice of Dr. McLellan.
Although some positive effects of caffeine on exercise perfor-
mance might have been reported in studies more than 2 decades
ago (as cited by Dr. McLellan), this seems to be challeneged by
more recent experiences, which have led to removing caffeine from
the doping list (2). We remain reluctant to comment on this,
because this parameter was beyond the scope of our study, which
was designed to assess the effect of caffeine on exercise-induced
myocardial perfusion response.
Furthermore, it has been brought to our attention that the
values for mean arterial pressure (MAP) in Table 1 of our report
were regrettably incorrect. The correct values are given in the
revised table (Table 1).
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Management of Women
With Acute Coronary Syndromes
In a recent study published in the Journal, Anand et al. (1) show
that women with acute coronary syndromes underwent less
coronary angiography and revascularization and had a higher
rate of refractory ischemia and rehospitalization than their male
counterparts. It is important to understand that these state-
ments are true—true, but not necessarily related. The difference
in total revascularization rates in high-risk female and male
populations was only 2.5%; this rate difference could not negate
the 8.6% difference in refractory ischemia/revascularization
rates between genders. Indeed, there is no direct evidence that
increasing the revascularization rate would change outcomes in
these women. As Anand et al. (1) point out, there is a relative
paucity of information regarding the appropriate treatment of
coronary artery disease in women. Moreover, their data dem-
onstrate the conundrum physicians face—namely, that women
have a lower prevalence of disease but are harder to treat
successfully.
Treatment mores demand that a treatment be of proven efficacy
and acceptable harm. If a physician hesitates in applying treatment
recommendations that are proven for men but not for women, to
a female patient, is that gender bias or good evidence-based
Table 1. Hemodynamics
Normoxia Hypoxia
Baseline Caffeine p Baseline Caffeine p
Rest
SBP (mm Hg) 124  12 120  11 NS 129  12 125  16 NS
DBP (mm Hg) 73  10 71  11 NS 69  8 70  11 NS
MAP (mm Hg) 90  9 87  8 NS 89  8 88  11 NS
HR (beats/min) 66  13 65  11 NS 77  11 78  21 NS
RPP (mm Hg  beats/min) 8,179  1,933 7,771  1,037 NS 9,996  2,265 9,860  3,362 NS
Peak exercise
SBP (mm Hg) 152  21 159  19 NS 152  11 154  10 NS
DBP (mm Hg) 90  9 95  4 NS 88  5 92  6 NS
MAP (mm Hg) 111  13 116  9 NS 110  6 112  7 NS
HR (beats/min) 153  4 154  8 NS 168  9 164  8 NS
RPP (mm Hg  beats/min) 23,173  3,487 24,382  2,360 NS 25,591  1,774 25,274  2,287 NS
Corrected values indicated in bold.
DBP  diastolic blood pressure; HR  heart rate; MAP  mean arterial blood pressure; RPP  rate pressure product; SBP  systolic blood pressure.
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